1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.
Google Scholar | Crossref2. Espay, AJ, Aybek, S, Carson, A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018; 75: 1132–1141.
Google Scholar | Crossref | Medline3. Stone, J, Burton, C, Carson, A. Recognising and explaining functional neurological disorder. BMJ 2020; 371: m3745.
Google Scholar | Medline4. Feinstein, A. Conversion disorder. Continuum (Minneap Minn) 2018; 24: 861–872.
Google Scholar | Medline5. Stone, J, Carson, A, Duncan, R, et al. Who is referred to neurology clinics? – the diagnoses made in 3781 new patients. Clin Neurol Neurosurg 2010; 112: 747–751.
Google Scholar | Crossref | Medline | ISI6. Gelauff, J, Stone, J. Prognosis of functional neurologic disorders. In: Hallet, M, Stone, J, Carson, A, (eds) Handbook of clinical neurology. 1st ed. Elsevier B.V., 2016, Vol. 139, pp.523–541.
Google Scholar7. Kleinstäuber, M, Witthöft, M, Steffanowski, A, et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev 2014; 11: CD010628.
Google Scholar8. Van Dessel, N, Den Boeſt, M, Van der Wouden, JC, et al. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev 2014; 11: CD011142.
Google Scholar | Crossref9. Kasper, S, Cubała, WJ, Fagiolini, A, et al. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. Epub ahead of print 12 November 2020. DOI: 10.1080/15622975.2020.1836399.
Google Scholar | Crossref10. EMA . Spravato® (esketamine) summary of product characteristics (Internet), https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf (2019, accessed 23 January 2021).
Google Scholar11. Molero, P, Ramos-Quiroga, JA, Martin-Santos, R, et al. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs 2018; 32: 411–420.
Google Scholar | Crossref | Medline12. Kurdi, M, Theerth, K, Deva, R. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res 2014; 8: 283.
Google Scholar | Crossref | Medline13. Mathai, DS, Meyer, MJ, Storch, EA, et al. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J Affect Disord 2020; 264: 123–129.
Google Scholar | Crossref | Medline14. Niciu, MJ, Shovestul, BJ, Jaso, BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord 2018; 232: 310–315.
Google Scholar | Crossref | Medline15. Ignácio, ZM, Réus, GZ, Arent, CO, et al. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br J Clin Pharmacol 2016; 82: 1280–1290.
Google Scholar | Crossref | Medline16. Sattar, Y, Wilson, J, Khan, AM, et al. A review of the mechanism of antagonism of N-methyl-D-aspartate receptor by ketamine in treatment-resistant depression. Cureus 2018; 10: e2652.
Google Scholar17. Del Rió-Casanova, L, González, A, Páramo, M, et al. Excitatory and inhibitory conversive experiences: neurobiological features involving positive and negative conversion symptoms. Rev Neurosci 2016; 27: 101–110.
Google Scholar | Crossref | Medline18. Bryson, A, Carter, O, Norman, T, et al. 5-HT2A agonists: a novel therapy for functional neurological disorders? Int J Neuropsychopharmacol 2017; 20: 422–427.
Google Scholar | Crossref | Medline19. Butler, M, Seynaeve, M, Nicholson, TR, et al. Psychedelic treatment of functional neurological disorder: a systematic review. Ther Adv Psychopharmacol 2020; 10: 204512532091212.
Google Scholar | SAGE Journals20. Stewart, B, Dean, JG, Koek, A, et al. Psychedelic-assisted therapy for functional neurological disorders: a theoretical framework and review of prior reports. Pharmacol Res Perspect 2020; 8: e00688.
Google Scholar | Crossref | Medline21. Sharpe, M, Stone, J, Hibberd, C, et al. Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcome. Psychol Med 2010; 40: 689–698.
Google Scholar | Crossref | Medline22. Vuilleumier, P. Brain circuits implicated in psychogenic paralysis in conversion disorders and hypnosis. Neurophysiol Clin 2014; 44: 323–337.
Google Scholar | Crossref | Medline23. Carhart-Harris, RL, Friston, KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 2019; 71: 316–344.
Google Scholar | Crossref | Medline24. Cohen, SP, Bhatia, A, Buvanendran, A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018; 43: 521–546.
Google Scholar | Crossref | Medline25. Tsui, P, Deptula, A, Yuan, DY. Conversion disorder, functional neurological symptom disorder, and chronic pain: comorbidity, assessment, and treatment. Curr Pain Headache Rep 2017; 21: 29.
Google Scholar | Crossref | Medline26. Stone, J, Hoeritzauer, I, Brown, K, et al. Therapeutic sedation for functional (psychogenic) neurological symptoms. J Psychosom Res 2014; 76: 165–168.
Google Scholar | Crossref | Medline